Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

The antipsychotic aripiprazole selectively prevents the stimulant and rewarding effects of morphine in mice

2014; Elsevier BV; Volume: 742; Linguagem: Inglês

10.1016/j.ejphar.2014.09.004

1879-0712

Ana F. Almeida‐Santos, Pedro H. Gobira, D Souza, Renata Cristina Mendes Ferreira, Thiago Roberto Lima Romero, Igor Dimitri Gama Duarte, Daniele C. Aguiar, Fabrício A. Moreira,

Neuroscience and Neuropharmacology Research

Aripiprazole is an antipsychotic that acts as a partial agonist at dopamine D2 receptors, with a favorable pharmacological profile. Due to its unique mechanism of action, this compound has potential application as a substitutive therapy for drug addiction. Considering that distinct neural systems subserve the addictive and analgesic actions of opioids, we tested the hypothesis that aripiprazole selectively inhibit the abuse-related, but not the antinociceptive, effects of morphine. The drugs were tested in male Swiss mice for their effects on locomotion, conditioned place preference (CPP) and nociception. Morphine (20 mg/kg) increased motor activity, whereas aripiprazole (0.1, 1 and 10 mg/kg) did not induce any change. This antipsychotic, however, prevented morphine-induced locomotion. In the conditioning box, aripiprazole did not induce either reward or aversion. Yet, it prevented both the acquisition and the expression of morphine-induced CPP. Finally, none of the doses of this antipsychotic interfere with morphine (5 mg/kg)-induced antinociception in the tail-flick test. In conclusion, aripiprazole inhibited the abuse-related effects of morphine at doses that do not interfere with basal locomotion, reward or aversion. Also, it did not alter morphine-induced antinociceptive effects. This antipsychotic should be further investigated as a possible substitutive strategy for treating certain aspects of opioid addiction.